Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism

European Journal of Endocrinology

Volumn 160, Issue 5, 2009, Pages 863-868

  Erem, Cihangir ^a   Kocak, Mustafa ^a   Nuhoglu, Irfan ^a   Yilmaz, Mustafa ^a   Ucuncu, Ozge ^a  

^a Faculty of Medicine   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; CALCIUM; CHLORIDE; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; PHOSPHORUS;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM CELL; FEMALE; FIBRINOLYSIS; HUMAN; MALE; MORTALITY; PHOSPHATE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; BLOOD; CASE CONTROL STUDY; MIDDLE AGED;

ADULT; CALCIUM; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; CHLORIDES; FEMALE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; LIPOPROTEINS; MALE; MIDDLE AGED; PHOSPHORUS; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 65549126677     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0069     Document Type: Article

References (47)

1. Andersson P, Rydberg E & Willenheimer R. Primary hyperparathyroidism and heart disease-a review. European Heart Journal 2004 25 1776-1787.
2. Hedback G & Oden A. Increased risk of death from primary hyperparathyroidism-an update. European Journal of Clinical Investigation 1998 28 271-276.
3. Kiernan TJ, O'Flynn AM, McDermott JH & Kearney P. Primary hyperparathyroidism and the cardiovascular system. International Journal of Cardiology 2006 113 E89-E92.
4. Rapado A. Arterial hypertension and primary hyperparathyroidism, incidence and follow-up after parathyroidectomy. American Journal of Nephrology 1986 6 (Suppl 1) 49-50.
5. Piovesan A, Molineri N, Casasso F, Emmolo I, Ugliengo G, Cesario F & Borretta G. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clinical Endocrinology 1999 50 321-328.
6. Stefenelli T, Abela C, Frank H, Koller-Strametz J, Globits S, Bergler-Klein J & Niederle B. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. Journal of Clinical Endocrinology and Metabolism 1997 82 106-112.
7. Baykan M, Erem C, Erdogan T, Hacihasanoglu A, Gedikli O, Kiris A, Kucukosmanoglu M, Ersoz HO & Celik S. Impairment of flow mediated vasodilatation of brachial artery in patients with primary hyperparathyroidism. International Journal of Cardiovascular Imaging 2007 23 323-328.
8. Kosch M, Hausberg M, Vormbrock K, Kisters K, Rahn KH & Barenbrock M. Studies on flow-mediated vasodilation and intimamedia thickness of the brachial artery in patients with primary hyperparathyroidism. American Journal of Hypertension 2000 13 759-764.
9. Chadwick DR, Harrison BJ, Chan P, Chong L & Peachell P. Vasoactive and proliferative effects of parathyroid hormone and parathyroid hormone-related peptide on human vascular smooth muscle. British Journal of Surgery 2000 87 1529-1533.
10. Lind L & Ljunghall S. Serum calcium and the ECG in patients with primary hyperparathyroidism. Journal of Electrocardiology 1994 27 99-103.
11. Procopio M, Magro G, Cesario F, Piovesan A, Pia A, Molineri N & Borretta G. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed type 2 diabetes mellitus in primary hyperparathyroidism. Diabetic Medicine 2002 19 958-961.
12. Chertok-Shacham E, Ishay A, Lavi I & Luboshitzky R. Biomarkers of hypercoagulability and inflammation in primary hyperparathyroidism. Medical Science Monitor 2008 14 CR628-CR632.
13. Hagstrom E, Lundgren E, Lithell H, Berglund L, Ljunghall S, Hellman P & Rastad J. Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over 5 years. Clinical Endocrinology 2002 56 253-260.
14. Grey AB, Evans MC, Stapleton JP & Reid IR. Body weight and bone mineral density in postmenopausal women with primary hyperparathyroidism. Annals of Internal Medicine 1994 121 745-749.
15. Erem C, Kocak M, Hacihasanoglu A, Yilmaz M, Saglam F & Ersoz HO. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-dimer levels. Experimental and Clinical Endocrinology and Diabetes 2008 116 619-624.
16. Wermers RA, Khosla S, Atkinson EJ, Grant CS, Hodgson SF, O'Fallon WM & Melton LJ. Survival after the diagnosis of hyperparathyroidism: a population-based study. American Journal of Medicine 1998 104 115-122.
17. Kamycheva E, Sundsfjord J & Jorde R. Serum parathyroid hormone levels predict coronary heart disease: the Tromso study. European Journal of Cardiovascular Prevention and Rehabilitation 2004 11 69-74.
18. Garcia de la Torre N, Wass JA & Turner HE. Parathyroid adenomas and cardiovascular risk. Endocrine Related Cancer 2003 10 309-322.
19. Fallo F, Camporese G, Capitelli E, Andreozzi GM, Mantero F & Lumachi F. Ultrasound evaluation of carotide artery in primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2003 88 2096-2099.
20. Lumachi E, Ermani M, Luisetto G, Nardi A, Basso SMM, Camozzi V & Favia G. Relationship between serum parathyroid hormone, serum calcium and arterial blood pressure in patients with primary hyperparathyroidism: results of a multivariate analysis. European Journal of Endocrinology 2002 146 643-647.
21. Hueper W. Metastatic calcifications in the organs of the dog after injections of parathyroid extract. Archives of Pathology 1927 3 14-25.
22. Hilgard P. Experimental hypercalcaemia and whole blood clotting. Journal of Clinical Pathology 1973 26 616-619.
23. Rooth E, Wallen H, Antovic A, von Arbin M, Kaponides G, Wahlgren N, Blombäck M & Antovic J. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Coagulation and Fibrinolysis 2007 18 365-370.
24. Redlitz A, Tan AK, Eaton DL & Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. Journal of Clinical Investigation 1995 96 2534-2538.
25. van Tilburg NH, Rosendaal FR & Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000 95 2855-2859.
26. Eichinger S, Schönauer V, Weltermann A, Minar E, Bialonczyk C, Hirschl M, Schneider B, Quehenberger P & Kyrle PA. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004 103 3773-3776.
27. Leebeek FW, Goor MP, Guimaraes AH, Brouwers GJ, Maat MP, Dippel DW & Rijken DC. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. Journal of Thrombosis and Haemostasis 2005 3 2211-2218.
28. Montaner J, Ribó M, Monasterio J, Molina CA & Alvarez-Sabín J. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 2003 34 1038-1040.
29. Ravindranath TM, Goto M, Iqbal O, Florian-Kujawski M, Hoppensteadt D, Hammadeh R, Sayeed MM & Fareed J. Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis. Clinical and Applied Thrombosis/Hemostasis 2007 13 362-368.
30. Broze GJ Jr. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Seminars in Hematology 1992 29 159-169.
31. Abumiya T, Yamaguchi T, Terasaki T, Kokawa T, Kario K & Kato H. Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patients. Thrombosis and Haemostasis 1995 74 1050-1054.
32. Kobayashi M, Wada H, Wakita Y, Shimura M, Nakase T, Hiyoyama K, Nagaya S, Minami N, Nakano T & Shiku H. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis 1995 73 10-14.
33. Harris GM, Stendt CL, Vollenhoven BJ, Gan TE & Tipping PG. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. American Journal of Hematology 1999 60 175-180.
34. Yamamoto C, Kaji T, Sakamoto M, Kozuka H & Koizumi F. Calcium regulation of tissue plasminogen activator and plasminogen activator inhibitor-1 release from cultured human vascular endothelial cells. Thrombosis Research 1994 74 163-168.
35. Muller B, Tsakiris DA, Roth CB, Guglielmetti M, Staub JJ & Marbet GA. Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. European Journal of Clinical Investigation 2001 31 131-137.
36. Thompson SG, Kienast J, Pyke SD, Haverkate F & van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. New England Journal of Medicine 1995 332 635-641.
37. Gelehrter TD & Sznycer-Laszuk R. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. Journal of Clinical Investigation 1986 77 165-169.
38. Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, Weiss HJ, Zareba W, Brown MW, Liang CS, Lichstein E, Little WC, Gillespie JA, Van Voorhees L, Krone RJ, Bodenheimer MM, Hochman J, Dwyer EM Jr, Arora R, Marcus FI, Watelet LF & Case RB. Thrombogenic factors and recurrent coronary events. Circulation 1999 99 2517-2522.
39. Feinbloom D & Bauer KA. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 2043-2053.
40. Kannel WB. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 2005 40 1215-1220.
41. Scarabin PY, Aillaud MF, Amouyel P, Evans A, Luc G, Ferrières J, Arveiler D & Juhan-Vague I. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10 500 male participants in a prospective study of myocardial infarction-the PRIME study. Prospective epidemiological study of myocardial infarction. Thrombosis and Haemostasis 1998 80 749-756.
42. Maroney SA & Mast AE. Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfusion and Apheresis Science 2008 38 9-14.
43. Lwaleed BA & Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. Journal of Pathology 2006 208 327-339.
44. Hoke M, Kyrle PA, Minar E, Bialonzcyk C, Hirschl M, Schneider B, Kollars M, Weltermann A & Eichinger S. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thrombosis and Haemostasis 2005 94 787-790.
45. Monasterio J, Bermúdez P, Quiroga D, Francisco E, Meneses B & Montaner J. Plasma thrombin-activatable fibrinolytic inhibitor (TAFI) among healthy subjects and patients with vascular diseases: a validation study. Pathophysiology of Haemostasis and Thrombosis 2003 33 382-386.
46. Bajzar L, Manuel R & Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. Journal of Biological Chemistry 1995 270 14477-14484.
47. Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegård A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A & Humphries SE, HIFMECH study group. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 867-873.